Bloomberg News

Bavarian Gets Rights to New Cancer Vaccine Product Candidates

October 05, 2011

Oct. 5 (Bloomberg) -- Bavarian Nordic A/S said its BN ImmunoTherapeutics subsidiary has agreed with the National Cancer Institute to jointly develop new off-the-shelf product candidates for the treatment of multiple cancers and a new technology platform based on NCI’s cancer vaccine technology.

Link to Statement:{NSN LSLLQ13V2800 <GO>}

To contact the editor responsible for this story: Christian Wienberg at cwienberg@bloomberg.net


Coke's Big Fat Problem
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus